Evaluation in 3 Months Duration of Neointimal Coverage After Zotarolimus-Eluting Stent Implantation by Optical Coherence Tomography: The ENDEAVOR OCT Trial

摘要: Objectives We performed this study to investigate the vascular response in early period after zotarolimus-eluting stent (ZES) (Endeavor Sprint, Medtronic CardioVascular, Minneapolis, Minnesota) implantation. Background The ZES has different characteristics, with biocompatible polymer and rapid drug-elution, compared first-generation drug-eluting stents (DES). Methods ENDEAVOR OCT (Evaluation 3 Months Duration of Neointimal Coverage Zotarolimus-Eluting Stent Implantation by Optical Coherence Tomography) trial is a prospective, single-center evaluating healing patterns optical coherence tomography (OCT) at months A total 31 30 patients underwent serial immediate post-intervention months. growth malapposition were analyzed each strut cross-sectional images 0.5-mm intervals. Results incidence was 6.0% 0.2%, respectively. However, late acquired not detected Of stents, 27 (87.1%) covered completely neointima, but remaining 4 had 2 (0.8%), (0.9%), (1.2%), 6 (1.4%) uncovered struts. Overall mean percentage struts 99.9 ± 0.4%. This finding consistent among groups acute coronary syndrome stable angina pectoris (99.9 0.3% vs. 0.4%, p = 0.92). Intracoronary thrombus documented 1 (3.2%) stents. Conclusions Most found Therefore, current demonstrated that might have favorable vivo Zotarolimus Eluting Using Tomography [ENDEAVOR OCT]; NCT00815139 )